Get the Stockscreener App
26.66
8.48%
2.085
Pre-market:
25.82
-0.845
-3.17%
Kodiak Sciences Inc stock is traded at $26.66, with a volume of 1.27M.
It is up +8.48% in the last 24 hours and down -1.79% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$24.58
Open:
$24.01
24h Volume:
1.27M
Relative Volume:
1.52
Market Cap:
$1.63B
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-7.0918
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
+21.20%
1M Performance:
-1.79%
6M Performance:
+181.28%
1Y Performance:
+432.24%
1-Day Range:
$23.70
$27.99
1-Week Range:
$21.51
$27.99
52-Week Range:
$1.92
$31.18
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
26.66 | 1.50B | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.27 | 119.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.38 | 83.75B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
847.26 | 52.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.37 | 44.12B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.48 | 39.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
History Review: Is Kodiak Sciences Inc a turnaround story2025 Performance Recap & Growth Focused Entry Reports - baoquankhu1.vn
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead - Yahoo Finance
Kodiak Sciences (NASDAQ:KOD) Shares Up 10.9%Should You Buy? - MarketBeat
GSA Capital Partners LLP Sells 76,735 Shares of Kodiak Sciences Inc. $KOD - MarketBeat
Will Kodiak Sciences Inc. benefit from seasonality2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - mfd.ru
Will Kodiak Sciences Inc. benefit from AI trendsQuarterly Investment Review & Low Risk Growth Stock Ideas - mfd.ru
Will Kodiak Sciences Inc. outperform the market in YEAREarnings Recap Summary & Verified Entry Point Signals - mfd.ru
Will Kodiak Sciences Inc. stock outperform tech sector in 2025July 2025 Weekly Recap & AI Enhanced Market Trend Forecasts - mfd.ru
Smart Money: Will Kodiak Sciences Inc benefit from AI trendsJuly 2025 Volume & Technical Pattern Alert System - baoquankhu1.vn
What are the analyst revisions for Kodiak Sciences Inc.Is BOIL stock a good investment in YEARJuly 2025 Technicals & Weekly Market Pulse Alerts - mfd.ru
Can Kodiak Sciences Inc. outperform in the next rally2025 Earnings Surprises & High Return Trade Guides - mfd.ru
H.C. Wainwright reiterates Buy rating on Kodiak Sciences stock at $38 - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Kodiak Sciences stock at $38 By Investing.com - Investing.com South Africa
KOD: HC Wainwright & Co. Reiterates Buy Rating with $38 Target | - GuruFocus
HC Wainwright Reaffirms Buy Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Entera Bio (ENTX) - The Globe and Mail
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares - Eastern Progress
KOD Stock Up 24% in 3 Months: Here's What You Need to Know - TradingView
Aug PostEarnings: Can Kodiak Sciences Inc lead its sector in growthEarnings Miss & Precise Entry and Exit Recommendations - baoquankhu1.vn
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Kodiak Sciences to present final APEX study results at Angiogenesis meeting - Investing.com Nigeria
Kodiak Sciences to present final APEX study results at Angiogenesis meeting By Investing.com - Investing.com South Africa
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 - marketscreener.com
Kodiak Sciences (KOD) Price Target Increased by 11.69% to 31.33 - Nasdaq
Kodiak Sciences raises capital through completed stock offering - MSN
Kodiak Sciences: A Stellar Move (NASDAQ:KOD) - Seeking Alpha
Aug Catalysts: Is Kodiak Sciences Inc exposed to currency risks2025 Volatility Report & Capital Protection Trading Alerts - baoquankhu1.vn
Aug Retail: Will Kodiak Sciences Inc outperform the market in YEAR - baoquankhu1.vn
Kodiak Sciences (NASDAQ:KOD) Trading 6.5% HigherHere's Why - MarketBeat
Can Kodiak Sciences (KOD) Funding And Readouts Reshape Its Retinal Disease Treatment Narrative? - Sahm
FY2025 EPS Estimates for Kodiak Sciences Lifted by Analyst - MarketBeat
Head to Head Review: Structure Therapeutics (NASDAQ:GPCR) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 7.6%Here's Why - MarketBeat
HC Wainwright Predicts Kodiak Sciences FY2030 Earnings - MarketBeat
Kodiak Sciences Reaches Analyst Target Price - Nasdaq
Kodiak Sciences stock price target raised to $38 from $26 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Kodiak Sciences stock price target raised to $38 from $26 at H.C. Wainwright - Investing.com Nigeria
KOD: Analyst Raises Price Target to $38 with Buy Rating | KOD St - GuruFocus
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Raises Target Price to $38 - 富途资讯
Kodiak Sciences (KOD) Valuation Check As Phase 3 Readouts And Capital Raise Focus Investor Attention - Sahm
Kodiak Sciences Is Riding A 325% Run Into Big Retina Readouts - Finimize
Aug Weekly: Is Kodiak Sciences Inc exposed to currency risksStop Loss & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Why Kodiak Sciences Inc. stock is in analyst buy zoneMarket Performance Report & Technical Analysis for Trade Confirmation - bollywoodhelpline.com
Chart Watch: Can Kodiak Sciences Inc lead its sector in growthJuly 2025 Technicals & Entry Point Confirmation Alerts - baoquankhu1.vn
Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Update - MarketBeat
First Week of December 18th Options Trading For Kodiak Sciences (KOD) - Nasdaq
Kodiak Sciences (KOD) Price Target Increased by 24.19% to 28.05 - Nasdaq
Is Kodiak Sciences Inc. (K27) stock included in top ETFsStock Screening Results & Exceptional Growth Portfolio - bollywoodhelpline.com
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):